Crearene AG and Alzchem Group AG: Creatine in dialysis patients - clinical study started
Dialysis is a standard method for cleaning a patient’s blood in case of chronic kidney disease (CKD). Scientific research and studies have demonstrated that dialysis patients who already suffer from a substantially reduced creatine level in their body because of the chronic kidney malfunction are further depleted in their creatine levels by the dialysis process.
Creatine is a natural substance which occurs regularly in the body and plays a vital role as both a means of energy transport and energy supply in human cells. There is a certain amount of creatine which can be picked up via fish and meat, but using nutritional supplementation as an additional source of creatine has proven useful, e. g. in cases of higher body performance requirements. Yet creatine also plays an important role for chronically ill people.
A clinical study has been launched with support from Crearene AG as part of the research cooperation between Alzchem Group AG and Crearene AG which has been in place since August 2022. The study is expected to evaluate the feasibility of adding creatine into the dialysis process and to explore effects.
The cooperation partners expect results of the study by year end. Based on the combination of the patented know-how of Crearene, result on many years of research in the field of creatine, and the manufacturing excellence of Alzchem the partners hope to be able to help dialysis patients globally: Today there are already three million people treated for CKD – with a rising long term trend.
Weblinks: https://crearene.com/ and https://www.alzchem.com/
Press release regarding the research cooperation between the partners.
https://crearene.com/wp-content/uploads/2022/08/pressemitteilung_alzchem_crearen_31-8-22_de.pdf
Contact
Sabine Sieber
Head of Investor Relations & Communications
Alzchem Group AG
Dr.-Albert-Frank-Str. 32
83308 Trostberg
Germany
About Alzchem
Alzchem is a globally active specialty chemicals company that is one of the market leaders in most of its fields of activity. Alzchem benefits from the three very different global developments climate change, population growth and longer life expectancy in a unique way. Alzchem products can offer attractive solutions for achieving the resulting social goals in a multitude of different applications.
The company sees interesting growth prospects for itself in the areas of human and animal nutrition and agriculture in particular. As a result of population growth, it is necessary to achieve efficient food production. Pharmaceutical raw materials and creatine products can contribute to a healthy old age as life expectancy increases. Alzchem is facing up to the goal of sustainability arising from climate change in the field of renewable energies and across the entire company. The fields of fine chemicals and metallurgy offer just as great a perspective.
Alzchem Group AG’s broad product range includes dietary supplements, precursors for corona tests and pharmaceutical raw materials. These products are the company's response to global trends and developments. Alzchem is ideally positioned in this respect and considers itself well prepared for an environmental future and global developments.
The company employs around 1,680 people at four production sites in Germany and a plant in Sweden, as well as three sales companies in the USA, China and England. Alzchem generated Group sales of around EUR 542.2 million and EBITDA of around EUR 61.4 million in 2022.